Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis
Complications associated with sickle cell disease (SCD) that are highly impactful for patients but until recently have been less understood include priapism, nephropathy, and neurologic injury. We conducted a retrospective study using US administrative claims data from July 01, 2013 through March 31...
Saved in:
| Published in | EJHaem Vol. 3; no. 4; pp. 1135 - 1144 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
John Wiley & Sons, Inc
01.11.2022
Wiley |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Complications associated with sickle cell disease (SCD) that are highly impactful for patients but until recently have been less understood include priapism, nephropathy, and neurologic injury. We conducted a retrospective study using US administrative claims data from July 01, 2013 through March 31, 2020 to analyze incidence of these complications, SCD treatment patterns, and healthcare resource utilization (HCRU) and costs among 2524 pediatric and adult patients with SCD (mean [SD] age 43.4 [22.4] years). The most common treatments during follow‐up were short‐acting opioids (54.0% of patients), red blood cell transfusion (15.9%), and hydroxyurea (11.0%). SCD complications occurred frequently; in the overall population, the highest follow‐up incidences per 1000 person‐years were for acute kidney injury (53.1), chronic kidney disease (40.6), and stroke (39.0). Complications occurred across all age groups but increased in frequency with age; notably, acute kidney injury was 69.7 times more frequent among ages 65+ than ages 0–15 (p < 0.001). Follow‐up per‐patient‐per‐month HCRU also increased with age; however, all‐cause healthcare costs were similarly high for all age groups and were driven primarily by inpatient stays. Patients with SCD across the age spectrum have a high burden of complications with the use of current treatments, suggesting unmet needs for treatment management. |
|---|---|
| AbstractList | Complications associated with sickle cell disease (SCD) that are highly impactful for patients but until recently have been less understood include priapism, nephropathy, and neurologic injury. We conducted a retrospective study using US administrative claims data from July 01, 2013 through March 31, 2020 to analyze incidence of these complications, SCD treatment patterns, and healthcare resource utilization (HCRU) and costs among 2524 pediatric and adult patients with SCD (mean [SD] age 43.4 [22.4] years). The most common treatments during follow‐up were short‐acting opioids (54.0% of patients), red blood cell transfusion (15.9%), and hydroxyurea (11.0%). SCD complications occurred frequently; in the overall population, the highest follow‐up incidences per 1000 person‐years were for acute kidney injury (53.1), chronic kidney disease (40.6), and stroke (39.0). Complications occurred across all age groups but increased in frequency with age; notably, acute kidney injury was 69.7 times more frequent among ages 65+ than ages 0–15 (p < 0.001). Follow‐up per‐patient‐per‐month HCRU also increased with age; however, all‐cause healthcare costs were similarly high for all age groups and were driven primarily by inpatient stays. Patients with SCD across the age spectrum have a high burden of complications with the use of current treatments, suggesting unmet needs for treatment management. Complications associated with sickle cell disease (SCD) that are highly impactful for patients but until recently have been less understood include priapism, nephropathy, and neurologic injury. We conducted a retrospective study using US administrative claims data from July 01, 2013 through March 31, 2020 to analyze incidence of these complications, SCD treatment patterns, and healthcare resource utilization (HCRU) and costs among 2524 pediatric and adult patients with SCD (mean [SD] age 43.4 [22.4] years). The most common treatments during follow‐up were short‐acting opioids (54.0% of patients), red blood cell transfusion (15.9%), and hydroxyurea (11.0%). SCD complications occurred frequently; in the overall population, the highest follow‐up incidences per 1000 person‐years were for acute kidney injury (53.1), chronic kidney disease (40.6), and stroke (39.0). Complications occurred across all age groups but increased in frequency with age; notably, acute kidney injury was 69.7 times more frequent among ages 65+ than ages 0–15 ( p < 0.001). Follow‐up per‐patient‐per‐month HCRU also increased with age; however, all‐cause healthcare costs were similarly high for all age groups and were driven primarily by inpatient stays. Patients with SCD across the age spectrum have a high burden of complications with the use of current treatments, suggesting unmet needs for treatment management. Abstract Complications associated with sickle cell disease (SCD) that are highly impactful for patients but until recently have been less understood include priapism, nephropathy, and neurologic injury. We conducted a retrospective study using US administrative claims data from July 01, 2013 through March 31, 2020 to analyze incidence of these complications, SCD treatment patterns, and healthcare resource utilization (HCRU) and costs among 2524 pediatric and adult patients with SCD (mean [SD] age 43.4 [22.4] years). The most common treatments during follow‐up were short‐acting opioids (54.0% of patients), red blood cell transfusion (15.9%), and hydroxyurea (11.0%). SCD complications occurred frequently; in the overall population, the highest follow‐up incidences per 1000 person‐years were for acute kidney injury (53.1), chronic kidney disease (40.6), and stroke (39.0). Complications occurred across all age groups but increased in frequency with age; notably, acute kidney injury was 69.7 times more frequent among ages 65+ than ages 0–15 (p < 0.001). Follow‐up per‐patient‐per‐month HCRU also increased with age; however, all‐cause healthcare costs were similarly high for all age groups and were driven primarily by inpatient stays. Patients with SCD across the age spectrum have a high burden of complications with the use of current treatments, suggesting unmet needs for treatment management. Complications associated with sickle cell disease (SCD) that are highly impactful for patients but until recently have been less understood include priapism, nephropathy, and neurologic injury. We conducted a retrospective study using US administrative claims data from July 01, 2013 through March 31, 2020 to analyze incidence of these complications, SCD treatment patterns, and healthcare resource utilization (HCRU) and costs among 2524 pediatric and adult patients with SCD (mean [SD] age 43.4 [22.4] years). The most common treatments during follow-up were short-acting opioids (54.0% of patients), red blood cell transfusion (15.9%), and hydroxyurea (11.0%). SCD complications occurred frequently; in the overall population, the highest follow-up incidences per 1000 person-years were for acute kidney injury (53.1), chronic kidney disease (40.6), and stroke (39.0). Complications occurred across all age groups but increased in frequency with age; notably, acute kidney injury was 69.7 times more frequent among ages 65+ than ages 0-15 ( < 0.001). Follow-up per-patient-per-month HCRU also increased with age; however, all-cause healthcare costs were similarly high for all age groups and were driven primarily by inpatient stays. Patients with SCD across the age spectrum have a high burden of complications with the use of current treatments, suggesting unmet needs for treatment management. Complications associated with sickle cell disease (SCD) that are highly impactful for patients but until recently have been less understood include priapism, nephropathy, and neurologic injury. We conducted a retrospective study using US administrative claims data from July 01, 2013 through March 31, 2020 to analyze incidence of these complications, SCD treatment patterns, and healthcare resource utilization (HCRU) and costs among 2524 pediatric and adult patients with SCD (mean [SD] age 43.4 [22.4] years). The most common treatments during follow-up were short-acting opioids (54.0% of patients), red blood cell transfusion (15.9%), and hydroxyurea (11.0%). SCD complications occurred frequently; in the overall population, the highest follow-up incidences per 1000 person-years were for acute kidney injury (53.1), chronic kidney disease (40.6), and stroke (39.0). Complications occurred across all age groups but increased in frequency with age; notably, acute kidney injury was 69.7 times more frequent among ages 65+ than ages 0-15 (p < 0.001). Follow-up per-patient-per-month HCRU also increased with age; however, all-cause healthcare costs were similarly high for all age groups and were driven primarily by inpatient stays. Patients with SCD across the age spectrum have a high burden of complications with the use of current treatments, suggesting unmet needs for treatment management.Complications associated with sickle cell disease (SCD) that are highly impactful for patients but until recently have been less understood include priapism, nephropathy, and neurologic injury. We conducted a retrospective study using US administrative claims data from July 01, 2013 through March 31, 2020 to analyze incidence of these complications, SCD treatment patterns, and healthcare resource utilization (HCRU) and costs among 2524 pediatric and adult patients with SCD (mean [SD] age 43.4 [22.4] years). The most common treatments during follow-up were short-acting opioids (54.0% of patients), red blood cell transfusion (15.9%), and hydroxyurea (11.0%). SCD complications occurred frequently; in the overall population, the highest follow-up incidences per 1000 person-years were for acute kidney injury (53.1), chronic kidney disease (40.6), and stroke (39.0). Complications occurred across all age groups but increased in frequency with age; notably, acute kidney injury was 69.7 times more frequent among ages 65+ than ages 0-15 (p < 0.001). Follow-up per-patient-per-month HCRU also increased with age; however, all-cause healthcare costs were similarly high for all age groups and were driven primarily by inpatient stays. Patients with SCD across the age spectrum have a high burden of complications with the use of current treatments, suggesting unmet needs for treatment management. Complications associated with sickle cell disease (SCD) that are highly impactful for patients but until recently have been less understood include priapism, nephropathy, and neurologic injury. We conducted a retrospective study using US administrative claims data from July 01, 2013 through March 31, 2020 to analyze incidence of these complications, SCD treatment patterns, and healthcare resource utilization (HCRU) and costs among 2524 pediatric and adult patients with SCD (mean [SD] age 43.4 [22.4] years). The most common treatments during follow-up were short-acting opioids (54.0% of patients), red blood cell transfusion (15.9%), and hydroxyurea (11.0%). SCD complications occurred frequently; in the overall population, the highest follow-up incidences per 1000 person-years were for acute kidney injury (53.1), chronic kidney disease (40.6), and stroke (39.0). Complications occurred across all age groups but increased in frequency with age; notably, acute kidney injury was 69.7 times more frequent among ages 65+ than ages 0–15 (p < 0.001). Follow-up per-patient-per-month HCRU also increased with age; however, all-cause healthcare costs were similarly high for all age groups and were driven primarily by inpatient stays. Patients with SCD across the age spectrum have a high burden of complications with the use of current treatments, suggesting unmet needs for treatment management. |
| Author | Wang, Sara Manwani, Deepa Anderson, Amy Saraf, Santosh L. Paulose, Jincy Yen, Glorian P. Burnett, Arthur L. Lee, Soyon Burton, Tanya |
| Author_xml | – sequence: 1 givenname: Deepa surname: Manwani fullname: Manwani, Deepa organization: The Children's Hospital at Montefiore – sequence: 2 givenname: Arthur L. surname: Burnett fullname: Burnett, Arthur L. organization: The Johns Hopkins University School of Medicine – sequence: 3 givenname: Jincy surname: Paulose fullname: Paulose, Jincy organization: Novartis Pharmaceuticals Corporation – sequence: 4 givenname: Glorian P. surname: Yen fullname: Yen, Glorian P. organization: Novartis Pharmaceuticals Corporation – sequence: 5 givenname: Tanya surname: Burton fullname: Burton, Tanya organization: Optum Life Sciences – sequence: 6 givenname: Amy surname: Anderson fullname: Anderson, Amy email: amy.j.anderson@optum.com organization: Optum Life Sciences – sequence: 7 givenname: Sara surname: Wang fullname: Wang, Sara organization: Optum Life Sciences – sequence: 8 givenname: Soyon surname: Lee fullname: Lee, Soyon organization: Novartis Pharmaceuticals Corporation – sequence: 9 givenname: Santosh L. orcidid: 0000-0002-8584-4194 surname: Saraf fullname: Saraf, Santosh L. organization: University of Illinois Hospital and Health Sciences System |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36467832$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kUtv1DAURiNUREupxC9AltiwyeB3YnajCmhRJRa0a8uPG-ohiQfbaTX_nmSmFFTBypZ97rm-_l5WR2McoapeE7wiGNP3m1tDV6IRz6oTKtu2loTLo7_2x9VZzhs8o4wIyciL6phJLpuW0ZPq7jqBKQOMBW1NKZDGjMzokZ2ShxHFDrk4bPvgTAlxucs5umAKeHQfyi3Kwf3oATnoe-RDBpPhA1qjm28oQUkxb8GVcDcDvQnDojb9Lof8qnremT7D2cN6Wt18-nh9flFfff18eb6-qh3nUtTKSiYb7DlTYCzpOuWYJZiCIp7NAGuBdcYyZnwDogNmJLfWe6ocJp2g7LS6PHh9NBu9TWEwaaejCXp_ENN3bVIJrgctG8U9l5h5TriQQhHHhVC2pWAVg3Z2vTu4tin-nCAXPYS8DG5GiFPWtOENxpIpNqNvn6CbOKV59j1FWzXHtQjfPFCTHcA_Pu93On86uvknc4LuESFYL9nrJXs9y2Z09QR1oewzK8mE_l8F9aHgPvSw-69Yf7lY04X_BbiYvf0 |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0304644 crossref_primary_10_1007_s40273_024_01385_9 crossref_primary_10_1111_bjh_20032 crossref_primary_10_1007_s40273_025_01474_3 crossref_primary_10_1111_aor_14880 crossref_primary_10_1007_s12033_025_01368_x crossref_primary_10_1080_17474086_2024_2385482 crossref_primary_10_1155_2024_4753349 crossref_primary_10_1007_s41669_024_00532_4 crossref_primary_10_1182_bloodadvances_2023010813 crossref_primary_10_1002_pds_5769 |
| Cites_doi | 10.36469/jheor.2020.13348 10.1001/jama.2014.10517 10.1093/aje/kwq433 10.1542/peds.2018-3285 10.1111/j.1365-2141.2009.07753.x 10.1056/NEJMra1510865 10.1097/01.md.0000189089.45003.52 10.1182/blood-2004-12-4973 10.1353/hpu.2021.0011 10.1001/jama.289.13.1645 10.1186/s13023-021-02096-6 10.1016/j.acap.2014.02.008 10.1002/ajh.26063 10.1186/1477-7525-4-59 10.1182/blood-2003-07-2475 10.1056/NEJM199505183322001 10.1080/13696998.2020.1813144 10.18553/jmcp.2020.20009 10.1001/jamanetworkopen.2019.15374 10.1186/s12955-019-1225-7 10.1111/bjh.15396 10.1001/jama.2010.378 10.1186/s12955-017-0713-x 10.1002/pds.4860 10.1002/ajh.21968 10.1016/j.jval.2021.02.014 10.1002/pbc.28703 10.1002/pbc.29493 10.1038/nrdp.2018.10 10.1542/peds.2013-0333 10.1002/ajh.24855 10.1002/ajh.21807 10.1159/000494581 10.1586/ehm.10.22 10.1177/2040620720955000 10.1186/s12887-019-1746-6 10.36469/jheor.2020.12852 10.1182/asheducation-2013.1.439 10.1182/asheducation-2016.1.625 10.1182/bloodadvances.2020001851 10.36469/10512 10.1371/journal.pone.0257796 10.1097/MPH.0b013e3182114c54 10.1001/jama.2015.3075 10.1002/ajh.21408 10.1371/journal.pone.0214355 10.1002/pbc.26369 10.1093/jpepsy/jsz031 10.1093/jpepsy/jsaa031 10.1097/01.NAJ.0000559779.40570.2c 10.2196/16319 10.1002/ajh.20336 |
| ContentType | Journal Article |
| Copyright | 2022 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd. 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2022 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd. – notice: 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. – notice: 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION NPM 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 DOA |
| DOI | 10.1002/jha2.575 |
| DatabaseName | Wiley Online Library Open Access CrossRef PubMed ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central ProQuest Central Student SciTech Premium Collection Biological Sciences Biological science database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | CrossRef PubMed MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2688-6146 |
| EndPage | 1144 |
| ExternalDocumentID | oai_doaj_org_article_6794d4603d41456591c4559b82eb93e8 36467832 10_1002_jha2_575 JHA2575 |
| Genre | article Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | 0R~ 1OC 24P 53G AAHHS ACCFJ ACCMX ACXQS ADKYN ADPDF ADZMN AEEZP AEQDE AFKRA AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AVUZU BBNVY BENPR BHPHI CCPQU EBS GROUPED_DOAJ HCIFZ IAO IHR INH ITC M7P M~E OVD OVEED PGMZT PIMPY RPM TEORI WIN AAFWJ AAYXX AFPKN CITATION PHGZM PHGZT NPM 8FE 8FH AAMMB ABUWG AEFGJ AGXDD AIDQK AIDYY AZQEC DWQXO GNUQQ LK8 PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c4465-9b63670d439eab1ff9c3b102e91d346538e3fab33ad7e5fe3a64bbdd29c01f523 |
| IEDL.DBID | 24P |
| ISSN | 2688-6146 |
| IngestDate | Wed Aug 27 01:30:33 EDT 2025 Fri Jul 11 08:02:05 EDT 2025 Wed Aug 13 04:20:40 EDT 2025 Thu Apr 03 07:08:44 EDT 2025 Thu Apr 24 22:58:19 EDT 2025 Tue Jul 01 04:19:27 EDT 2025 Wed Jan 22 16:22:43 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | retrospective studies United States healthcare costs opioid use organ dysfunction sickle cell disease |
| Language | English |
| License | Attribution 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4465-9b63670d439eab1ff9c3b102e91d346538e3fab33ad7e5fe3a64bbdd29c01f523 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-8584-4194 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjha2.575 |
| PMID | 36467832 |
| PQID | 2742895758 |
| PQPubID | 5066168 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6794d4603d41456591c4559b82eb93e8 proquest_miscellaneous_2747006393 proquest_journals_2742895758 pubmed_primary_36467832 crossref_primary_10_1002_jha2_575 crossref_citationtrail_10_1002_jha2_575 wiley_primary_10_1002_jha2_575_JHA2575 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | November 2022 2022-11-00 2022-Nov 20221101 2022-11-01 |
| PublicationDateYYYYMMDD | 2022-11-01 |
| PublicationDate_xml | – month: 11 year: 2022 text: November 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | EJHaem |
| PublicationTitleAlternate | EJHaem |
| PublicationYear | 2022 |
| Publisher | John Wiley & Sons, Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley |
| References | 2021; 24 2009; 84 2010; 303 2019; 14 2019; 17 2019; 19 2016; 2016 1995; 332 2020; 11 2020; 7 2020; 4 2021; 32 2018; 4 2013; 2013 2005; 106 2020; 9 2019; 28 2014; 14 2019; 119 2020; 45 2010; 3 2003; 289 2005; 79 2017; 64 2018; 182 2004; 103 2019; 6 2019; 2 2005; 84 2011; 33 2006; 4 2017; 376 2011; 173 2021; 96 2014; 312 2010; 85 2019; 144 2021; 16 2017; 92 2017; 15 2015; 313 2019; 44 2020 2019; 47 2011; 86 2019 2020; 26 2017 2009; 146 2020; 67 2020; 23 2013; 132 2022;; 69 e_1_2_10_23_1 e_1_2_10_46_1 e_1_2_10_21_1 e_1_2_10_44_1 e_1_2_10_42_1 e_1_2_10_40_1 e_1_2_10_2_1 e_1_2_10_4_1 e_1_2_10_18_1 e_1_2_10_53_1 e_1_2_10_6_1 e_1_2_10_16_1 e_1_2_10_39_1 e_1_2_10_55_1 e_1_2_10_8_1 e_1_2_10_14_1 e_1_2_10_37_1 e_1_2_10_13_1 e_1_2_10_34_1 e_1_2_10_11_1 e_1_2_10_32_1 Agency for Healthcare Research and Quality (e_1_2_10_29_1) 2017 e_1_2_10_30_1 e_1_2_10_51_1 e_1_2_10_27_1 e_1_2_10_25_1 e_1_2_10_48_1 e_1_2_10_24_1 e_1_2_10_45_1 e_1_2_10_22_1 e_1_2_10_43_1 e_1_2_10_20_1 e_1_2_10_41_1 e_1_2_10_52_1 e_1_2_10_3_1 e_1_2_10_19_1 e_1_2_10_54_1 e_1_2_10_5_1 e_1_2_10_17_1 e_1_2_10_38_1 e_1_2_10_56_1 e_1_2_10_7_1 e_1_2_10_15_1 e_1_2_10_36_1 e_1_2_10_12_1 e_1_2_10_35_1 e_1_2_10_9_1 e_1_2_10_10_1 e_1_2_10_33_1 e_1_2_10_31_1 e_1_2_10_50_1 e_1_2_10_28_1 e_1_2_10_49_1 e_1_2_10_26_1 e_1_2_10_47_1 |
| References_xml | – volume: 84 start-page: 323 issue: 6 year: 2009 end-page: 7 article-title: The cost of health care for children and adults with sickle cell disease publication-title: Am J Hematol – volume: 14 start-page: S61 issue: 5 year: 2014 end-page: 7 article-title: Identifying sickle cell disease cases using administrative claims publication-title: Acad Pediatr – volume: 15 start-page: 136 issue: 1 year: 2017 article-title: Adherence to hydroxyurea, health‐related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross‐sectional study in adolescents and young adults publication-title: Health Qual Life Outcomes – volume: 28 start-page: 1246 issue: 9 year: 2019 end-page: 50 article-title: National trends in hydroxyurea and opioid prescribing for sickle cell disease by office‐based physicians in the United States, 1997–2017 publication-title: Pharmacoepidemiol Drug Saf – volume: 9 issue: 7 year: 2020 article-title: Integration of mobile health into sickle cell disease care to increase hydroxyurea utilization: protocol for an efficacy and implementation study publication-title: JMIR Res Protoc – volume: 84 start-page: 363 issue: 6 year: 2005 end-page: 76 article-title: Outcome of sickle cell anemia: a 4‐decade observational study of 1056 patients publication-title: Medicine (Baltimore) – volume: 132 start-page: 677 issue: 4 year: 2013 end-page: 83 article-title: Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia publication-title: Pediatrics – volume: 19 start-page: 354 issue: 1 year: 2019 article-title: HABIT efficacy and sustainability trial, a multi‐center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol publication-title: BMC Pediatr – volume: 96 start-page: 404 issue: 4 year: 2021 end-page: 17 article-title: Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: results from the international Sickle Cell World Assessment Survey (SWAY) publication-title: Am J Hematol – volume: 2013 start-page: 439 year: 2013 end-page: 46 article-title: Transfusion therapy for sickle cell disease: a balancing act publication-title: Hematology Am Soc Hematol Educ Program – volume: 376 start-page: 1561 issue: 16 year: 2017 end-page: 73 article-title: Sickle cell disease publication-title: N Engl J Med – volume: 64 issue: 6 year: 2017 article-title: Health‐related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease publication-title: Pediatr Blood Cancer – volume: 17 start-page: 155 issue: 1 year: 2019 article-title: Treatment patterns and economic burden of sickle‐cell disease patients prescribed hydroxyurea: a retrospective claims‐based study publication-title: Health Qual Life Outcomes – volume: 106 start-page: 2269 issue: 7 year: 2005 end-page: 75 article-title: Long‐term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study publication-title: Blood – volume: 144 issue: 1 year: 2019 article-title: Hydroxyurea use for sickle cell disease among Medicaid‐enrolled children publication-title: Pediatrics – volume: 146 start-page: 300 issue: 3 year: 2009 end-page: 5 article-title: Silent infarcts in young children with sickle cell disease publication-title: Br J Haematol – volume: 16 start-page: 460 issue: 1 year: 2021 article-title: A systematic literature review of frequency of vaso‐occlusive crises in sickle cell disease publication-title: Orphanet J Rare Dis – volume: 4 start-page: 59 year: 2006 article-title: Hydroxyurea and sickle cell anemia: effect on quality of life publication-title: Health Qual Life Outcomes – volume: 24 start-page: 1095 issue: 8 year: 2021 end-page: 101 article-title: Indirect economic burden of sickle cell disease publication-title: Value Health – volume: 85 start-page: 797 issue: 10 year: 2010 end-page: 9 article-title: The burden of emergency department use for sickle‐cell disease: an analysis of the national emergency department sample database publication-title: Am J Hematol – volume: 6 start-page: 174 issue: 3 year: 2019 end-page: 84 article-title: High healthcare utilization in adolescents with sickle cell disease prior to transition to adult care: a retrospective study publication-title: J Health Econ Outcomes Res – volume: 4 year: 2018 article-title: Sickle cell disease publication-title: Nat Rev Dis Primers – volume: 7 start-page: 52 issue: 1 year: 2020 end-page: 60 article-title: Medical resource use and costs of treating sickle cell‐related vaso‐occlusive crisis episodes: a retrospective claims study publication-title: J Health Econ Outcomes Res – volume: 33 start-page: 251 issue: 4 year: 2011 end-page: 4 article-title: Differences in health‐related quality of life in children with sickle cell disease receiving hydroxyurea publication-title: J Pediatr Hematol Oncol – volume: 103 start-page: 2039 issue: 6 year: 2004 end-page: 45 article-title: Sustained long‐term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease publication-title: Blood – volume: 14 issue: 7 year: 2019 article-title: Sickle cell disease complications: prevalence and resource utilization publication-title: PLoS One – year: 2019 – volume: 69 year: 2022; article-title: Burden of central nervous system complications in sickle cell disease: a systematic review and meta‐analysis publication-title: Pediatr Blood Cancer – volume: 7 start-page: 94 issue: 1 year: 2020 end-page: 101 article-title: Association between vaso‐occlusive crises and opioid prescriptions among patients with sickle cell disease: a retrospective claims‐based study publication-title: J Health Econ Outcomes Res – volume: 3 start-page: 255 issue: 3 year: 2010 end-page: 60 article-title: Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities publication-title: Expert Rev Hematol – volume: 2 issue: 11 year: 2019 article-title: Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease publication-title: JAMA Netw Open – volume: 2016 start-page: 625 issue: 1 year: 2016 end-page: 31 article-title: Sickle cell disease: when and how to transfuse publication-title: Hematology Am Soc Hematol Educ Program – volume: 47 start-page: 205 issue: 1‐3 year: 2019 end-page: 13 article-title: Sickle cell nephropathy in the pediatric population publication-title: Blood Purif – volume: 11 year: 2020 article-title: Current and novel therapies for the prevention of vaso‐occlusive crisis in sickle cell disease publication-title: Ther Adv Hematol – volume: 182 start-page: 259 issue: 2 year: 2018 end-page: 70 article-title: Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6‐year population‐based cohort study publication-title: Br J Haematol – volume: 79 start-page: 17 issue: 1 year: 2005 end-page: 25 article-title: Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance publication-title: Am J Hematol – volume: 312 start-page: 1033 issue: 10 year: 2014 end-page: 48 article-title: Management of sickle cell disease: summary of the 2014 evidence‐based report by expert panel members publication-title: JAMA – volume: 26 start-page: 1121 issue: 9 year: 2020 end-page: 9 article-title: The economic burden of end‐organ damage among Medicaid patients with sickle cell disease in the United States: a population‐based longitudinal claims study publication-title: J Manag Care Spec Pharm – volume: 86 start-page: 273 issue: 3 year: 2011 end-page: 7 article-title: Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease publication-title: Am J Hematol – volume: 67 issue: 12 year: 2020 article-title: Administrative data identify sickle cell disease: a critical review of approaches in U.S. health services research publication-title: Pediatr Blood Cancer – volume: 16 issue: 10 year: 2021 article-title: Profile of Medicaid enrollees with sickle cell disease: a high need, high cost population publication-title: PLoS One – volume: 23 start-page: 1345 issue: 11 year: 2020 end-page: 55 article-title: Vaso‐occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance ‐ the perspective of private and public payers publication-title: J Med Econ – volume: 332 start-page: 1317 issue: 20 year: 1995 end-page: 22 article-title: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia publication-title: N Engl J Med – volume: 173 start-page: 676 issue: 6 year: 2011 end-page: 82 article-title: Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries publication-title: Am J Epidemiol – volume: 45 start-page: 593 issue: 6 year: 2020 end-page: 606 article-title: A systematic review of medication adherence interventions in pediatric sickle cell disease publication-title: J Pediatr Psychol – volume: 4 start-page: 2656 issue: 12 year: 2020 end-page: 701 article-title: American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain publication-title: Blood Adv – volume: 289 start-page: 1645 issue: 13 year: 2003 end-page: 51 article-title: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment publication-title: JAMA – volume: 32 start-page: 99 issue: 1 year: 2021 end-page: 118 article-title: Hydroxyurea adherence strategies for persons with sickle cell disease: a systematic review publication-title: J Health Care Poor Underserved – volume: 44 start-page: 948 issue: 8 year: 2019 end-page: 58 article-title: Cognitive function in sickle cell disease across domains, cerebral infarct status, and the lifespan: a meta‐analysis publication-title: J Pediatr Psychol – volume: 303 start-page: 1288 issue: 13 year: 2010 end-page: 94 article-title: Acute care utilization and rehospitalizations for sickle cell disease publication-title: JAMA – year: 2020 – volume: 119 start-page: 26 issue: 6 year: 2019 end-page: 35 article-title: Understanding the complications of sickle cell disease publication-title: Am J Nurs – volume: 313 start-page: 1671 issue: 16 year: 2015 end-page: 2 article-title: Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea publication-title: JAMA – year: 2017 – volume: 92 start-page: E584 issue: 10 year: 2017 end-page: 90 article-title: Prospective evaluation of chronic organ damage in adult sickle cell patients: a seven‐year follow‐up study publication-title: Am J Hematol – ident: e_1_2_10_50_1 doi: 10.36469/jheor.2020.13348 – ident: e_1_2_10_30_1 – ident: e_1_2_10_16_1 doi: 10.1001/jama.2014.10517 – ident: e_1_2_10_28_1 doi: 10.1093/aje/kwq433 – ident: e_1_2_10_40_1 doi: 10.1542/peds.2018-3285 – ident: e_1_2_10_33_1 doi: 10.1111/j.1365-2141.2009.07753.x – ident: e_1_2_10_2_1 doi: 10.1056/NEJMra1510865 – ident: e_1_2_10_25_1 doi: 10.1097/01.md.0000189089.45003.52 – ident: e_1_2_10_17_1 doi: 10.1182/blood-2004-12-4973 – ident: e_1_2_10_54_1 doi: 10.1353/hpu.2021.0011 – ident: e_1_2_10_19_1 doi: 10.1001/jama.289.13.1645 – ident: e_1_2_10_37_1 doi: 10.1186/s13023-021-02096-6 – ident: e_1_2_10_27_1 doi: 10.1016/j.acap.2014.02.008 – ident: e_1_2_10_5_1 doi: 10.1002/ajh.26063 – ident: e_1_2_10_47_1 doi: 10.1186/1477-7525-4-59 – ident: e_1_2_10_18_1 doi: 10.1182/blood-2003-07-2475 – ident: e_1_2_10_20_1 doi: 10.1056/NEJM199505183322001 – ident: e_1_2_10_31_1 doi: 10.1080/13696998.2020.1813144 – ident: e_1_2_10_9_1 doi: 10.18553/jmcp.2020.20009 – ident: e_1_2_10_4_1 – ident: e_1_2_10_6_1 doi: 10.1001/jamanetworkopen.2019.15374 – ident: e_1_2_10_11_1 doi: 10.1186/s12955-019-1225-7 – ident: e_1_2_10_45_1 doi: 10.1111/bjh.15396 – ident: e_1_2_10_15_1 doi: 10.1001/jama.2010.378 – ident: e_1_2_10_48_1 doi: 10.1186/s12955-017-0713-x – ident: e_1_2_10_41_1 doi: 10.1002/pds.4860 – ident: e_1_2_10_43_1 doi: 10.1002/ajh.21968 – ident: e_1_2_10_10_1 doi: 10.1016/j.jval.2021.02.014 – ident: e_1_2_10_26_1 doi: 10.1002/pbc.28703 – ident: e_1_2_10_36_1 doi: 10.1002/pbc.29493 – ident: e_1_2_10_3_1 doi: 10.1038/nrdp.2018.10 – ident: e_1_2_10_44_1 doi: 10.1542/peds.2013-0333 – ident: e_1_2_10_24_1 doi: 10.1002/ajh.24855 – ident: e_1_2_10_22_1 doi: 10.1002/ajh.21807 – ident: e_1_2_10_35_1 doi: 10.1159/000494581 – ident: e_1_2_10_52_1 doi: 10.1586/ehm.10.22 – ident: e_1_2_10_51_1 doi: 10.1177/2040620720955000 – ident: e_1_2_10_55_1 doi: 10.1186/s12887-019-1746-6 – ident: e_1_2_10_8_1 doi: 10.36469/jheor.2020.12852 – ident: e_1_2_10_39_1 doi: 10.1182/asheducation-2013.1.439 – volume-title: Clinical Classifications Software (CCS) for ICD‐9‐CM/ICD‐10‐CM year: 2017 ident: e_1_2_10_29_1 – ident: e_1_2_10_38_1 doi: 10.1182/asheducation-2016.1.625 – ident: e_1_2_10_13_1 doi: 10.1182/bloodadvances.2020001851 – ident: e_1_2_10_32_1 doi: 10.36469/10512 – ident: e_1_2_10_7_1 doi: 10.1371/journal.pone.0257796 – ident: e_1_2_10_46_1 doi: 10.1097/MPH.0b013e3182114c54 – ident: e_1_2_10_42_1 doi: 10.1001/jama.2015.3075 – ident: e_1_2_10_12_1 doi: 10.1002/ajh.21408 – ident: e_1_2_10_23_1 doi: 10.1371/journal.pone.0214355 – ident: e_1_2_10_49_1 doi: 10.1002/pbc.26369 – ident: e_1_2_10_34_1 doi: 10.1093/jpepsy/jsz031 – ident: e_1_2_10_53_1 doi: 10.1093/jpepsy/jsaa031 – ident: e_1_2_10_21_1 doi: 10.1097/01.NAJ.0000559779.40570.2c – ident: e_1_2_10_56_1 doi: 10.2196/16319 – ident: e_1_2_10_14_1 doi: 10.1002/ajh.20336 |
| SSID | ssj0002315631 |
| Score | 2.2889476 |
| Snippet | Complications associated with sickle cell disease (SCD) that are highly impactful for patients but until recently have been less understood include priapism,... Abstract Complications associated with sickle cell disease (SCD) that are highly impactful for patients but until recently have been less understood include... |
| SourceID | doaj proquest pubmed crossref wiley |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1135 |
| SubjectTerms | Age Blood Blood transfusion Codes Emergency medical care Enrollments Erythrocytes Health care Health care policy healthcare costs Hydroxyurea Ischemia Kidney diseases Medicare Nephropathy opioid use organ dysfunction Pain Patients Pediatrics Pharmacy Resource utilization retrospective studies Sickle cell disease United States |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQbyIb-uLCKKnYtuk7cbbKsoi6EUXvIWkmYC6dmVd_f3OpO2yguLFaxPadGaS-SaZ-cLYcSrKnq8yjE6cV7FElxYrAB8nUOZKOZmlngqcb--KwVDePOaPc1d9UU5YQw_cCO6sQINxskiEkymhD5VWElGw7WVglYBQ5os-by6Yeg4kLhiXiLRjm02ys2cqXM0pnXDO_wSa_p-w5XeoGnzN9SpbaUEi7zeDW2MLUK-zpdv2GHyDfT506eH8LfBj1u_c1I7bUJPAx55_yxTnptUBOE77rhw18zICTpv2vD2hOed9PrznE5hOxl31Ja9G5umVXt0Ql2yy4fXVw-Ugbi9QiCviQYuVLYifzSHoAGNR6qoSFhEFqNQJIlbrgfDGCmFcCbkHYQpprXOZqpLUY4i6xRbrcQ07jENlS4qNFKA-JGSmENZYXC5y1ELiZcROO7HqqmUXp0suRrrhRc40KUCjAiJ2NOv51jBq_NDngjQzaycO7PAALUO3lqH_soyI7Xd61e3EfNd0Mt1T-AlsPpo145QikZsaxh-hTxmgm4jYdmMPs5GIAj0LroIROwkG8usv6JtBH5fDfPc_fmWPLWdUdhFqIPfZ4nTyAQcIhqb2MNj9F-JiBR4 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9QwDI_gJiFeEN8UBgoSgqdqbZN-hBd0Q5tOkzYh2El7i5LGmYCjPe5u_P3YaVqYNHhto8qNY_sXx_6FsTe5qBvfFrg7cV6lEkNaqgB8mkFdKuVkkXtqcD49qxZLeXJRXsSE2zaWVY4-MThq17eUIz-gI8VGIbhoPqx_pnRrFJ2uxis0brM9dMFNM2N7h0dnnz5PWRZEL2Ul8pF1NisOvlEDa0llhX_FoUDXfxPGvA5ZQ8w5vs_uRbDI54N2H7Bb0D1kd07jcfgj9ut8LBPn68CT2W256Ry3oTeB955fqxjnJuoCHKf8K0cNfV8Bp-Q9jyc17_mcL7_wDew2_diFyduV-fqDPj0QmDxmy-Oj84-LNF6kkLbEh5YqWxFPm0PwAcbi7KtWWEQWoHIniGCtAeGNFcK4GkoPwlTSWucK1Wa5x63qEzbr-g6eMQ6trWmPpAANWUJhKmGNRbdRWiUyLxP2bpxW3UaWcbrsYqUHfuRCkwI0KiBhr6eR64FZ44Yxh6SZ6T1xYYcH_eZSR9PSFUriZJUJJ3PCpypvJe6TbFMAygRNwvZHvepooFv9ZzmhHNNrNC2actNBfxXG1AHCiYQ9HdbDJImoMMKgN0zY27BA_vkL-mQxR7dYPv-_FC_Y3YIaK0KX4z6b7TZX8BLhzs6-imv6Nxqm_68 priority: 102 providerName: ProQuest |
| Title | Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjha2.575 https://www.ncbi.nlm.nih.gov/pubmed/36467832 https://www.proquest.com/docview/2742895758 https://www.proquest.com/docview/2747006393 https://doaj.org/article/6794d4603d41456591c4559b82eb93e8 |
| Volume | 3 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEBZtAqWX0nfdposCpT2Z2JIsW71tSsISSAhtFnITkjUuabd22N3093dGfpSFFHq1xrbs0cx8Gmk-MfYhl2XV1AJnJ6ExqcKQlhqAJs2gLIwJSuQNFTifX-jFUp1dF9fDrkqqhen5IaaEG1lG9Ndk4M5vjv6Shv6gSlQEGw_ZPlXW0nY-oS6n_ArilkLH4wiFxsGAUUiP3LOZOBpv3olGkbT_PqS5C1xj5Dl9yp4MkJHPex0_Yw-gfc4enQ-L4i_Y76txszi_jWyZ7Ya7NnAfKxR41_CdfePcDRqBwCkLy1FPP1fAKYXPh_Waz3zOl9_4GrbrbqzF5PXK3fyiR_c0Ji_Z8vTk6ssiHY5TSGtiRUuN18TWFhCCgPOoA1NLj_gCTB4k0axVIBvnpXShhKIB6bTyPgRh6ixvcML6iu21XQtvGIfalzRTMoDmrEA4Lb3z6DwKb2TWqIR9Gn-rrQeucTryYmV7lmRhSQEWFZCww0nytufXuEfmmDQztRMjdrzQrb_bwcCsxp4EpTMZVE4o1eS1wtmSrwRgn6BK2MGoVzuY6cbSOnVl8BXYfDg1o4HRL3ctdHdRpoxATibsdT8epp5IjXEGfWLCPsYB8s9PsGeLOTrH4u3_Cr5jjwUVWsSqxwO2t13fwXuEP1s_i-N8xvaPTy4uv85iEmEWs1R_ADcoAxU |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELaqrQS8IG4CBYzE8RQ1sZ3DSAhtodX22BWCXalvwY4nqGVJlt0tiD_Fb2QmF1QqvPU1saKJZzyHZ-Ybxp6FMkmLXGB04grtKzRpvgYo_ACSSGunRFhQg_N4Eo9m6uA4Ot5gv7peGCqr7HRirahdldMd-TalFFONzkX6ZvHNp6lRlF3tRmg0YnEIP39gyLZ6vf8O-ftciL3d6duR304V8HMCB_O1jQm0zKElBmORFJ1Li2YWdOgkoY2lIAtjpTQugagAaWJlrXNC50FYRAR0gCp_U8k4EAO2ubM7ef-hv9VBbymKZdih3AZi-5QaZiMqY_zL7tXjAS7yac-7yLWN27vBrrfOKR820nSTbUB5i10Zt-n32-z7tCtL54sal7NccVM6buteCF4V_FyFOjct78Fxuu_lKBFf5sApWcDbzNArPuSzj3wJ62XVdX3yfG5OvtKnG8CUO2x2KVt8lw3KqoT7jENuE4rJNKDiUCBMLK2xqKYiq2VQKI-97LY1y1tUcxquMc8aPGaREQMyZIDHnvYrFw2SxwVrdogz_XvC3q4fVMvPWXuUsxgpcSoOpFMh-cM6zBXGZTYVgDRB6rGtjq9ZqxBW2R_xRTr613iUactNCdVZvSapXUbpsXuNPPSUyBgtGmpfj72oBeSfv5AdjIaohqMH_6fiCbs6mo6PsqP9yeFDdk1QU0fdYbnFBuvlGTxCV2ttH7fyzdmnyz5SvwEUxTz1 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqrVRxQbwJFDASj1O0SZyXkRDa0q62LV1V0JV6S-14jIAlWXa3IP4av46ZxAlUKtx6Taxo4hnPwzPzDWPPQpHltowwOjFW-jGaNF8CWD-ALJHSxFFoqcH5aJpOZvHBaXK6wX51vTBUVtnpxEZRm7qkO_IhpRRzic5FPrSuLOJ4d_xm8c2nCVKUae3GabQicgg_f2D4tnq9v4u8fh5F472TtxPfTRjwSwIK86VOCcDMoFUGpZEsWQqNJhdkaAQhj-UgrNJCKJNBYkGoNNbamEiWQWgTAj1A9b-ZUVQ0YJs7e9Pj9_0ND3pOSSrCDvE2iIafqXk2oZLGv2xgMyrgMv_2orvc2LvxDXbdOap81ErWTbYB1S22deRS8bfZ95OuRJ0vGozOasVVZbhu-iJ4bfmFanWunByA4XT3y1E6vsyBU-KAuyzRKz7isw98Cetl3XWA8nKuPn2lT7fgKXfY7Eq2-C4bVHUF9xmHUmcUn0lAJRJDpFKhlUaVlWgpAht77GW3rUXpEM5p0Ma8aLGZo4IYUCADPPa0X7loUT0uWbNDnOnfEw5386BefizcsS5SpMTEaSBMHJJvLMMyxhhN5xEgTZB7bLvja-GUw6r4I8pIR_8ajzVtuaqgPm_WZI37KDx2r5WHnhKRonVDTeyxF42A_PMXioPJCFVy8uD_VDxhW3iUinf708OH7FpE_R1Ns-U2G6yX5_AIva61fuzEm7Ozqz5RvwG1KUEq |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+patterns+and+burden+of+complications+associated+with+sickle+cell+disease%3A+A+US+retrospective+claims+analysis&rft.jtitle=EJHaem&rft.au=Manwani%2C+Deepa&rft.au=Burnett%2C+Arthur+L.&rft.au=Paulose%2C+Jincy&rft.au=Yen%2C+Glorian+P.&rft.date=2022-11-01&rft.issn=2688-6146&rft.eissn=2688-6146&rft.volume=3&rft.issue=4&rft.spage=1135&rft.epage=1144&rft_id=info:doi/10.1002%2Fjha2.575&rft.externalDBID=10.1002%252Fjha2.575&rft.externalDocID=JHA2575 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2688-6146&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2688-6146&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2688-6146&client=summon |